Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.

Dr Marc-Antoine DELBARRE - Médecin Interniste CHU Amiens
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.  https://pubmed.ncbi.nlm.nih.gov/35908242/
PMID : 35908242